The huge benefit to our disease agnostic approach means that in time we can use our approach to understand the pattern of a wide range of diseases.
Collectively the joint teams combine the very best scientific, clinical, technological and computational expertise from the University of Oxford and GSK, using technologically advanced tools and innovative research methodologies.
Already they have started to improve tools in, and knowledge from, genetics, genomics, molecular and single cell biology, spatial imaging, machine learning and novel methods of data handling to study the pattern of diseases in new ways.
Every day we see how this new model of collaboration is enabling us to be nimbler and more flexible than ever before. As a result, enabling findings are being delivered early in the life of the programme.
We know that the work being done now by our world class research scientists has the potential to help prioritise those early R&D programmes most likely to succeed and match them to patients most likely to respond.
Finding new and better ways to help patients is at the very heart of everything we do.